Skip to main content

Table 4 Changes in the safety parameters (N = 100)

From: Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data

 

Baseline

3 months

p value

White blood cell count (/µL)

6914

(1753.7)

6747

(1941.1)

0.210

Red blood cell count (104/µL)

490.9

(52.4)

486.8

(51.3)

0.076

Hemoglobin (g/dL)

14.8

(1.6)

14.6

(1.5)

< 0.001

Hematocrit (%)

45.7

(4.5)

45.1

(4.3)

0.005

Platelet count (104/µL)

24.8

(6.0)

26.2

(6.4)

< 0.001

Serum albumin (g/dL)

4.46

(0.3)

4.54

(0.3)

0.001

LDH (U/L)

172.9

(35.2)

169.8

(36.8)

0.292

BUN (mg/dL)

15.1

(3.5)

15.2

(3.3)

0.760

CK (U/L)

106.5

(82.0)

112.2

(92.9)

0.249

  1. Data are mean (standard deviation) values. P values are for comparisons between baseline and 3 months after the start of pemafibrate
  2. LDH, lactate dehydrogenase; BUN, urea nitrogen; CK, creatine kinase
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us